Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
DEPO [NASD]
DepoMed Inc.
Index- P/E11.54 EPS (ttm)1.34 Insider Own0.10% Shs Outstand58.74M Perf Week3.07%
Market Cap908.12M Forward P/E49.08 EPS next Y0.32 Insider Trans- Shs Float58.51M Perf Month1.58%
Income78.90M PEG0.38 EPS next Q-0.02 Inst Own85.20% Short Float14.18% Perf Quarter3.00%
Sales236.40M P/S3.84 EPS this Y241.50% Inst Trans9.38% Short Ratio7.53 Perf Half Y33.39%
Book/sh4.50 P/B3.44 EPS next Y-41.67% ROA17.80% Target Price17.50 Perf Year90.63%
Cash/sh9.42 P/C1.64 EPS next 5Y30.00% ROE52.30% 52W Range7.68 - 16.00 Perf YTD46.12%
Dividend- P/FCF- EPS past 5Y34.10% ROI32.30% 52W High-3.37% Beta1.46
Dividend %- Quick Ratio5.40 Sales past 5Y31.00% Gross Margin94.00% 52W Low101.30% ATR0.48
Employees291 Current Ratio5.50 Sales Q/Q37.30% Oper. Margin36.60% RSI (14)57.86 Volatility2.35% 3.24%
OptionableYes Debt/Eq0.91 EPS Q/Q0.00% Profit Margin41.00% Rel Volume0.64 Prev Close15.17
ShortableYes LT Debt/Eq0.91 EarningsNov 05 AMC Payout0.00% Avg Volume1.10M Price15.46
Recom2.00 SMA202.65% SMA503.71% SMA20014.44% Volume702,122 Change1.91%
Jul-10-14Initiated WallachBeth Buy $17
Feb-25-13Downgrade WallachBeth Buy → Hold $8 → $7
Jan-05-12Initiated JMP Securities Mkt Outperform $8
Sep-30-11Initiated Auriga Buy $10
Feb-18-10Downgrade Merriman Buy → Neutral
Oct-21-09Initiated Caris & Company Buy $9
Oct-12-09Reiterated Merriman Buy $11.50 → $7.50
Oct-05-09Initiated Merriman Buy
Jun-20-08Initiated Roth Capital Buy $5
Mar-15-07Reiterated Thomas Weisel Overweight $8 → $6.50
Nov-20-14 04:05PM  Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference PR Newswire
Nov-14-14 01:04PM  DEPOMED INC Financials EDGAR Online Financials
Nov-12-14 08:00AM  Depomed To Present At Stifel 2014 Healthcare Conference PR Newswire
Nov-08-14 07:07PM  10-Q for Depomed, Inc. Company Spotlight
Nov-06-14 04:28PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report EDGAR Online
10:05AM  Another Solid Quarter For Depomed Zacks Small Cap Research
Nov-05-14 05:42PM  Depomed beats Street 3Q forecasts AP
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:11PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Depomed Reports Third Quarter 2014 Financial Results PR Newswire
07:07AM  Q3 2014 Depomed Inc Earnings Release - After Market Close CCBN
Oct-27-14 04:01PM  Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014 PR Newswire
Oct-07-14 12:08PM  5 places to play momentum at MarketWatch
Oct-03-14 12:00AM  OxyContin, Cialis Makers Dodge Court to Beat Patent Suits at Bloomberg
Oct-01-14 11:14AM  [video] Dan Tana's: Hollywood's Iconic Red-Sauce Joint at MarketWatch
Sep-30-14 02:54PM  Accelerated selling means its time to move to cash at MarketWatch
Sep-17-14 04:07PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
Sep-09-14 04:05PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex EDGAR Online
Sep-05-14 05:00PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
02:34PM  Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for GraliseĀ® (Gabapentin) PR Newswire
Sep-04-14 07:38AM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:00AM  Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021 PR Newswire
Sep-02-14 04:18PM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
04:00PM  Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 PR Newswire
Aug-25-14 04:01PM  Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference PR Newswire
Aug-21-14 04:02PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
Aug-19-14 04:35PM  Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs Benzinga +13.53%
04:03PM  Nasdaq stocks posting largest percentage increases AP
11:32AM  Why DepoMed (DEPO) Stock Is Gaining Today at TheStreet
11:15AM  Depomed Prevails in GraliseĀ® ANDA Litigation Blocking Generic Entry Until 2024 PR Newswire
Aug-06-14 04:43PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:05PM  Depomed Reports Second Quarter 2014 Financial Results PR Newswire
07:07AM  Q2 2014 Depomed Earnings Release - After Market Close CCBN
Aug-04-14 05:08PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
04:01PM  Depomed Announces Appointment of R. Scott Shively as Chief Commercial Officer PR Newswire
Jul-25-14 04:01PM  Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 PR Newswire
Jul-17-14 05:27PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events EDGAR Online
05:15PM  2 Small-Cap Stocks Hedge Funds Love at Motley Fool
03:38PM  Depomed Announces District Court Order in ANDA Litigation PR Newswire
Jul-16-14 08:03AM  Depomed appoints Srinivas Rao as Chief Medical Officer theflyonthewall.com
08:00AM  Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer PR Newswire
Jul-10-14 06:46AM  Coverage initiated on DepoMed by WallachBeth Briefing.com
Jul-09-14 09:04AM  Immune Pharma: A Top-Pick Based On Pipeline And Valuation at Seeking Alpha
Jun-27-14 06:03PM  Martin Marietta Materials Set to Join the S&P 500; United States Steel Corp. Set to Join the S&P MidCap 400 and Depomed Inc. Set to Join the S&P SmallCap 600 PR Newswire
Jun-20-14 04:06PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jun-18-14 09:37AM  Exclusive: Steven Burrill Removed From Control Of Venture Fund For Unauthorized Payments at Forbes
08:00AM  Depomed To Present AT JMP Securities 2014 Healthcare Conference PR Newswire
Jun-10-14 11:00AM  TBUFF: A Pharmaceutical Company With Strong Upside Potential Zacks Small Cap Research
08:00AM  Depomed to Present at Wells Fargo 2014 Healthcare Conference PR Newswire
May-28-14 08:14AM  Mallinckrodt's NDA accepted by FDA, triggering $5M payment to Depomed at theflyonthewall.com
08:10AM  Mallinckrodt New Drug Application For MNK-155 Accepted For Review By FDA PR Newswire
May-27-14 04:05PM  Depomed To Present At Jefferies 2014 Global Healthcare Conference PR Newswire
May-23-14 05:07PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securit EDGAR Online
May-13-14 10:03AM  Perilous Reversal Stock: DepoMed (DEPO) at TheStreet -5.58%
May-12-14 09:51AM  DepoMed (DEPO) Is Today's Dead Cat Bounce Stock at TheStreet +13.53%
May-09-14 04:36PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report EDGAR Online -15.64%
04:01PM  Depomed To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare Conference PR Newswire
03:40PM  Review Of Depomed's First Quarter Results - Mind The GAAP at Seeking Alpha
01:12PM  Why DepoMed Inc. Shares Were Rocked at Motley Fool
May-08-14 08:00PM  DepoMed's (DEPO) CEO James Schoeneck on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha -9.27%
05:00PM  Depomed Earnings Call scheduled for 5:00 pm ET today CCBN
04:30PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:19PM  Depomed sees FY14 adjusted EPS 0c-16c, one estimate 31c at theflyonthewall.com
04:18PM  Depomed reports Q1 adjusted EPS (1c), one estimate 10c at theflyonthewall.com
04:01PM  Depomed Reports First Quarter 2014 Financial Results PR Newswire
09:02AM  Today's Top Health Care Stocks to Watch: Depomed Inc., Dendreon Corp., and Jazz Pharmaceuticals at Motley Fool
07:07AM  Q1 2014 Depomed Earnings Release - After Market Close CCBN
May-06-14 05:17PM  Depomed May Be Setting Up In A New Base at Investor's Business Daily
Apr-30-14 04:05PM  Depomed To Report First Quarter Fiscal Year 2014 Financial Results On Thursday, May 8, 2014 PR Newswire
Apr-14-14 01:04PM  Why DepoMed Inc. Shares Temporarily Spiked Higher at Motley Fool
08:07AM  Depomed enters into settlement agreement with two Gralise's ANDA filers theflyonthewall.com
08:00AM  Depomed Announces Settlements with Two GraliseĀ® ANDA Filers PR Newswire
Apr-10-14 03:28PM  Averages, leading issues dictate high caution at MarketWatch -7.12%
Apr-04-14 10:17AM  Today's Dead Cat Bounce Stock Is DepoMed (DEPO) at TheStreet
Mar-31-14 03:45AM  BioDelivery Sciences: 4 Different Insiders Have Sold Shares This Month at Seeking Alpha
Mar-25-14 05:52PM  Depomed A 'Turtle' Gaining In Specialty Pharma Race at Investor's Business Daily
Mar-17-14 05:53PM  Depomed: 3 Different Insiders Have Sold Shares This Month at Seeking Alpha
04:45PM  DEPOMED INC Files SEC form 10-K, Annual Report EDGAR Online
Mar-16-14 05:16PM  Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook at Seeking Alpha
Mar-14-14 11:41AM  Put This Specialty Pharma In Your Portfolio at Seeking Alpha
Mar-13-14 09:09AM  Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc. at Motley Fool +10.67%
Mar-12-14 06:50PM  DepoMed Management Discusses Q4 2013 Results - Earnings Call Transcript Optionetics
04:36PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:30PM  Depomed Earnings Call scheduled for 4:30 pm ET today CCBN
04:01PM  Depomed Reports Fourth Quarter and Full Year 2013 Financial Result PR Newswire
08:45AM  Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) PR Newswire
07:07AM  Q4 2013 Depomed Earnings Release - After Market Close CCBN
Mar-10-14 05:30PM  Depomed To Report Fourth Quarter Fiscal Year 2013 Financial Results On Wednesday, March 12, 2014 PR Newswire
Mar-05-14 04:15PM  Depomed To Present At The 26th Annual ROTH Conference On Monday, March 10, 2014 PR Newswire
01:13PM  Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array PR Newswire
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other conditions, and diseases of the central nervous system in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Lazanda (fentanyl) Nasal Spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is also involved in the clinical development of DM-1992 that completed a Phase II trial for Parkinson's disease. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. It has license and collaboration agreements with Abbott Products Inc.; Santarus, Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceutica N.V.; Janssen Pharmaceuticals, Inc.; Mallinckrodt; Patheon Puerto Rico, Inc.; and Valeant Pharmaceuticals International, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gosling Matthew MSenior VP, General CounselNov 19Option Exercise6.1771,000438,07088,211Nov 21 08:00 PM
Gosling Matthew MSenior VP, General CounselNov 19Sale15.3671,0001,090,34717,211Nov 21 08:00 PM
Schoeneck James APresident and CEOAug 01Option Exercise6.1130,000183,30042,898Aug 04 10:46 AM
Vargas Thadd MSenior VP, BDMay 16Option Exercise3.0939,040120,63453,119May 19 05:34 PM
Gosling Matthew MSenior VP, General CounselMay 09Option Exercise6.174,00024,68015,396May 09 07:37 PM
Schoeneck James APresident and CEOMay 09Option Exercise4.5330,000135,750126,306May 09 07:37 PM
Vargas Thadd MSenior VP, BDMar 14Option Exercise5.0810,00050,80077,948Mar 14 08:46 PM
Gosling Matthew MSenior VP, General CounselMar 14Option Exercise3.0921,87567,59433,271Mar 14 08:46 PM
Vargas Thadd MSenior VP, BDMar 14Sale14.6963,869938,21014,079Mar 14 08:46 PM
Schoeneck James APresident and CEOMar 14Sale14.5417,000247,12499,306Mar 14 08:45 PM
Gosling Matthew MSenior VP, General CounselMar 14Sale14.7421,875322,32811,396Mar 14 08:46 PM
Gosling Matthew MSenior VP, General CounselDec 02Sale8.405,69247,83611,396Dec 04 04:51 PM
Vargas Thadd MSenior VP, BDDec 02Sale8.405,29644,50861,698Dec 04 04:50 PM
Sweeney Michael MDCMO and VP, R&DDec 02Sale8.404,27035,8789,084Dec 04 04:50 PM
Schoeneck James APresident and CEODec 02Sale8.4017,192144,454116,306Dec 04 04:51 PM
Moretti August JChief Financial OfficerDec 02Sale8.402,82123,70911,214Dec 04 04:51 PM